Bristol-Myers Squibb Company(BMY)Stock Performance & ReturnsNYSE
Returns, drawdowns and benchmark comparison
Peer Comparison
Relative scale, growth, and profitability vs sector peers
| Ticker | Market Cap | P/E Ratio | Revenue Growth | Net Margin | EPS | ROE | Debt/Equity | Dividend Yield | 52W High | 52W Low |
|---|---|---|---|---|---|---|---|---|---|---|
BMY | 121.95 B | 13.36x | 5.70% | 18.87% | $4.47 | 46.60% | 2.02x | 4.08% | $68.64 | $42.52 |
LLY | 1.06 T | 40.23x | 47.70% | 33.53% | $29.55 | 102.29% | 1.62x | 0.56% | $1292.65 | $778.94 |
JNJ | 622.84 B | 30.66x | 6.60% | 21.48% | $8.43 | 25.74% | 0.58x | 2.03% | $281.07 | $178.91 |
MRK | 352.29 B | 115.15x | 5.10% | 4.77% | $1.24 | 6.96% | 1.28x | 2.31% | $156.00 | $79.67 |
PFE | 159.59 B | 37.33x | 2.60% | 6.80% | $0.75 | 5.01% | 0.74x | 6.12% | $29.21 | $22.57 |
Peer Valuation & Performance Analysis
Peer group analysis for Bristol-Myers Squibb Company (BMY) compared to its primary competitors (including LLY, JNJ, MRK) reveals distinct metrics. BMY trades at a valuation discount relative to its competitors, with a P/E ratio of 13.4x versus the peer average of 55.8x (representing a 76% discount). This discount might represent an undervalued entry opportunity or reflect specific risk factors the market is discounting. In terms of growth, BMY's revenue growth of 5.7% lags behind the peer average of 15.5%, indicating potential market share losses or slower industry adoption. Additionally, it boasts superior profitability with a net margin of 18.9% compared to the peer average of 16.6%, demonstrating strong cost controls and pricing power.
Peer Performance Rankings
Ranking comparison across key performance metrics
P/E Ratio (Lower is Better)
Revenue Growth
Net Profit Margin
Financial Rankings Summary
• BMY ranks #1 in P/E ratio, #3 in revenue growth, and #3 in profit margins
• Average ranking: #2 - 🎯 Top-tier fundamentals relative to peer group
• Rankings based on actual financial data from company reports
Historical Trading Data
Price and volume data with customizable timeframes
Showing 15 of 15 trading sessions from the last 15 days
| Date | Open | High | Low | Close | Volume | Daily Change |
|---|---|---|---|---|---|---|
| 2026-10-07 | $59.45 | $60.10 | $59.01 | $59.70 | 11,091,200 | +0.18% |
| 2026-10-06 | $58.94 | $59.60 | $58.64 | $59.59 | 9,885,400 | +1.33% |
| 2026-10-05 | $59.89 | $60.15 | $58.33 | $58.81 | 19,237,900 | -3.83% |
| 2026-10-02 | $60.66 | $61.24 | $60.24 | $61.15 | 9,933,500 | +0.53% |
| 2026-10-01 | $61.56 | $61.97 | $60.62 | $60.83 | 10,768,200 | -1.51% |
| 2026-09-30 | $62.63 | $63.47 | $61.76 | $61.76 | 15,867,300 | -0.73% |
| 2026-09-29 | $62.93 | $63.24 | $61.31 | $62.22 | 15,835,700 | -1.60% |
| 2026-09-28 | $62.13 | $63.27 | $61.66 | $63.23 | 14,018,700 | +1.62% |
| 2026-09-25 | $61.12 | $62.27 | $60.77 | $62.22 | 10,672,800 | +1.16% |
| 2026-09-24 | $61.40 | $61.59 | $60.60 | $61.50 | 14,901,900 | +0.57% |
| 2026-09-23 | $62.31 | $62.65 | $61.08 | $61.15 | 15,842,800 | -1.77% |
| 2026-09-22 | $62.73 | $63.08 | $62.03 | $62.25 | 15,235,100 | -0.59% |
| 2026-09-21 | $63.09 | $63.40 | $62.62 | $62.62 | 6,837,900 | -0.70% |
| 2026-09-18 | $62.71 | $63.07 | $62.19 | $63.06 | 36,849,600 | +0.35% |
| 2026-09-17 | $64.08 | $64.35 | $62.52 | $62.84 | 12,211,300 | -1.19% |
Explore More Analysis for BMY
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.